Prognosis of hepatitis B-related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents

Background and Aim:  We investigated long‐term outcomes and prognostic factors in patients with hepatitis B virus (HBV)‐related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. Methods:  Between January 1999 and February 2009, a total of 240 consecutive patients who had HBV‐...

Full description

Saved in:
Bibliographic Details
Published in:Journal of gastroenterology and hepatology 2012-10, Vol.27 (10), p.1589-1595
Main Authors: Kim, Chang Ha, Um, Soon Ho, Seo, Yeon Seok, Jung, Jin Yong, Kim, Jin Dong, Yim, Hyung Joon, Keum, Bora, Kim, Yong Sik, Jeen, Yoon Tae, Lee, Hong Sik, Chun, Hoon Jai, Kim, Chang Duck, Ryu, Ho Sang
Format: Article
Language:English
Subjects:
Administration, Oral
Adult
Antiviral Agents - administration & dosage
Carcinoma, Hepatocellular - virology
DNA, Viral - blood
Female
Hepatitis B virus
Hepatitis B virus - genetics
Hepatitis B, Chronic - complications
Hepatitis B, Chronic - diagnosis
Hepatitis B, Chronic - drug therapy
Hepatitis B, Chronic - mortality
hepatitis B-related liver cirrhosis
Humans
Kaplan-Meier Estimate
lamivudine
Lamivudine - administration & dosage
Liver Cirrhosis - diagnosis
Liver Cirrhosis - drug therapy
Liver Cirrhosis - mortality
Liver Cirrhosis - virology
Liver Neoplasms - virology
Male
Middle Aged
Multivariate Analysis
Nucleotides - administration & dosage
oral antiviral agent
prognosis
Proportional Hazards Models
Retrospective Studies
Risk Assessment
Risk Factors
Time Factors
Treatment Outcome
Viral Load
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and Aim:  We investigated long‐term outcomes and prognostic factors in patients with hepatitis B virus (HBV)‐related liver cirrhosis in the era of oral nucleos(t)ide analog antiviral agents. Methods:  Between January 1999 and February 2009, a total of 240 consecutive patients who had HBV‐related cirrhosis without malignancy were treated with lamivudine and second line nucleos(t)ide analogs. The group of historical controls consisted of 481 consecutive patients with HBV‐related cirrhosis who were managed without any antiviral treatment prior to 1999. Results:  In 78% of the patients who received antiviral treatment, sustained viral suppression (serum HBV DNA
ISSN:0815-9319
1440-1746
DOI:10.1111/j.1440-1746.2012.07167.x